RxDoctor Payments Data

Bradford Gwyther, PA

Medical · Albuquerque, NMNPI 1356381701

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,017 of the $4,187 with a category attached, or 72.1%. Medtronic accounts for 61.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $2,572 and has fallen 69.0% since, to $797 in 2025. Among medical clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,187in general payments, 2019–2025

Across 136 payments — averaging $30.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$821
  • Abbott$246
  • Novartis$160
  • Biosense Webster, Inc.$92
  • Amgen$76
  • plus $233 from 10 others

What the payments were for

  • Travel & lodging$1,17028%
  • Food & beverage$3,01772%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,187 in reported general payments places this provider in the 90th percentile of 156 medical providers in New Mexico.

See all medical providers in New Mexico

Medicare billing

Part B allowed, 2024
$140,568
Medicare patients
883
Services billed
2,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban953$992,079
XareltoRivaroxaban234$276,526
EntrestoSacubitril/Valsartan14$24,566
Dofetilide79$21,656
Metoprolol Succinate584$9,007
Flecainide Acetate286$7,969
Atorvastatin Calcium239$3,428
Carvedilol370$3,394
Losartan Potassium222$2,868
Diltiazem 24hr Er (Cd)Diltiazem Hcl124$2,180
Spironolactone200$1,788
Lisinopril181$1,599
Amlodipine Besylate150$1,143
Furosemide151$1,055
Eplerenone14$1,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$992,079953 claims
NovartisEntresto$160$24,56614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 156 medical providers in New Mexico.

Other medical in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →